When combined with anticancer agents, targeted therapies, or immune checkpoint inhibitors, HSP90 inhibitors exert powerful synergistic effects by modulating patient tumor protein degradation and resistance-related pathways. The gene discussed is HSP90AB1; the disease is neoplasm.